Recently, the Guangdong Province Department of Industry and Information Technology released a public notice revealing the list of Specialized and Sophisticated Small and Medium-sized Enterprises (SMEs) for 2022, among the listed companies, Pluslife Biotech was once again honoured with the title of "2022 Guangdong Province Specialized and Sophisticated SMEs".

The criteria for being designated as a Specialized and Sophisticated SME involves possessing a high level of specialization, refinement, and distinctive development as well as innovation ability. Pluslife Biotech was acknowledged by the provincial authorities for its innovative technology and exceptional performances in the field of in-vitro diagnostic (IVD).

The Pluslife Market Focus, Molecular POCT

Since its establishment, Pluslife has honed in on the niche area of IVD, specifically in the realm of molecular diagnostics. The company is dedicated to developing unique and innovative molecular diagnostic products using next-generation genetic technologies, providing a complete solution from core protein R&D, molecular diagnostic methodologies research and development, to molecular POCT products.

Brand Empowered by Independent R&D and Product Differentiation

Pluslife is committed to maintaining a focus on independent research and production to establish a world-class brand of Molecular POCT. The raw materials of diagnostic enzymes are produced in-house at an industrial scale. By incorporating Pluslife's patented technology RHAM, the company successfully developed the "Mini Dock," a Next-Generation Molecular POCT Analyzer. The Mini Dock is capable of diagnosing respiratory infections, sexually transmitted infections (STIs), and animal diseases. In comparison to other molecular diagnostic products, the Mini Dock has several advantages, including portability, higher accuracy and sensitivity, ease of operation, multi-pathogen detection, and affordability. It also addresses common issues of other molecular diagnostic products, such as the need for expensive equipment, professional operator, and lengthy testing process.

Continuous Innovations through Experienced Talents and Management

Currently, Pluslife has filed for more than 100 patents related to RHAM technology and other technologies, of which over 20 have been granted. These patented technologies are the result of the expertise and hard work of the company's talented R&D team. The founder of Pluslife, Professor Song Yangzhou, has a strong professional and technical background, having published over 170 articles in international top journals such as Cell, Nature, and Science, with a total of 22,000+ citations and an H-index of 66. Furthermore, more than 60% of the company's employees are engaged in the work of R&D, which holds a great promise for the company's continuous innovation. By collaborating effectively with the R&D team and enterprise management team, scientific research results can be efficiently industrialized

Being recognized with the award of "2022 Guangdong Province Specialized and Sophisticated SMEs" demonstrates Pluslife's high level of specialization, exceptional innovation capabilities, and growth potential. Moving forward, Pluslife aims to deepen the business track of molecular POCT, optimize the quality management system, and extend the application based on the patented RHAM technology to create a better healthcare system for all.